RxDoctor Payments Data

Kelly Guest, APRN

Nurse Practitioner · Louisville, KYNPI 1437541703

Payments from drug & device makers

$1,594in general payments, 2019–2025

Across 26 payments — averaging $61.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$227
  • AbbVie$199
  • AstraZeneca$162
  • Astellas Pharma US Inc$137
  • Idorsia Pharmaceuticals US Inc$120
  • Novo Nordisk$120
  • plus $630 from 8 others

What the payments were for

  • Food & beverage$1,594100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,594 in reported general payments places this provider in the 75th percentile of 1,918 nurse practitioner providers in Kentucky.

See all nurse practitioner providers in Kentucky

Medicare billing

Part B allowed, 2024
$64,215
Medicare patients
203
Services billed
1,025

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban61$63,432
OzempicSemaglutide48$46,517
JardianceEmpagliflozin28$41,348
VascepaIcosapent Ethyl15$15,988
LinzessLinaclotide15$15,085
TrulicityDulaglutide13$13,599
Breo ElliptaFluticasone/Vilanterol21$11,594
SymbicortBudesonide/Formoterol Fumarate20$10,062
TradjentaLinagliptin11$7,834
Atorvastatin Calcium340$2,828
Advair DiskusFluticasone Propion/Salmeterol14$2,497
Levothyroxine Sodium189$2,150
Gabapentin132$1,679
Metoprolol Succinate95$1,454
Albuterol Sulfate HfaAlbuterol Sulfate56$1,440

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$20$63,43261 claims
Novo NordiskOzempic$120$46,51748 claims
AbbVieLinzess, Synthroid$199$15,83031 claims
Lilly USA, LLCTrulicity, Olanzapine$227$14,06026 claims
GSKBreo Ellipta$111$11,59421 claims
AstraZenecaSymbicort$162$10,06220 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$19$2,150189 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,918 nurse practitioner providers in Kentucky.

Other nurse practitioner in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →